Long-term safety of risankizumab from 17 clinical trials in patients with moderate-to-severe plaque psoriasis.
Long-term safety of risankizumab from 17 clinical trials in patients with moderate-to-severe plaque psoriasis. Br J Dermatol. 2022 03; 186(3):466-475.